The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo

D. K. Coletta, M. Fernandez, E. Cersosimo, A. Gastaldelli, N. Musi, R. A. Defronzo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. We hypothesized that muraglitazar would increase expression of 5′-monophosphate-activated protein kinase and genes involved in adiponectin signalling, free fatty acid oxidation and mitochondrial function in skeletal muscle. Methods: Sixteen participants with Type 2 diabetes received muraglitazar, 5 mg/day (n = 12) or placebo (n = 4). Before and after 16 weeks, participants had vastus lateralis muscle biopsy followed by 180 min euglycaemic hyperinsulinaemic clamp. Results: Muraglitazar increased plasma adiponectin (9.0 ± 1.1 to 17.8 ± 1.5 μg/ml, P < 0.05), while no significant change was observed with placebo. After 16 weeks with muraglitazar, fasting plasma glucose declined by 31%, fasting plasma insulin decreased by 44%, insulin-stimulated glucose disposal increased by 81%, HbA<inf>1c</inf> decreased by 21% and plasma triglyceride decreased by 39% (all P < 0.05). Muraglitazar increased mRNA levels of 5′-monophosphate-activated protein kinase, adiponectin receptor 1, adiponectin receptor 2, peroxisome proliferator-activated receptor gamma coactivator-1 alpha and multiple genes involved in mitochondrial function and fat oxidation. In the placebo group, there were no significant changes in expression of these genes. Conclusions: Muraglitazar increases plasma adiponectin, stimulates muscle 5′-monophosphate-activated protein kinase expression and increases expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation. These changes represent important cellular mechanisms by which dual peroxisome proliferator-activated receptor agonists improve skeletal muscle insulin sensitivity.

Original languageEnglish (US)
Pages (from-to)657-664
Number of pages8
JournalDiabetic Medicine
Volume32
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Adiponectin
Skeletal Muscle
Fats
Adiponectin Receptors
Protein Kinases
Genes
Peroxisome Proliferator-Activated Receptors
Type 2 Diabetes Mellitus
Insulin Resistance
Placebos
Gene Expression
Muscles
Glucose Clamp Technique
Quadriceps Muscle
Nonesterified Fatty Acids
muraglitazar
Triglycerides
Biopsy
Messenger RNA

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. / Coletta, D. K.; Fernandez, M.; Cersosimo, E.; Gastaldelli, A.; Musi, N.; Defronzo, R. A.

In: Diabetic Medicine, Vol. 32, No. 5, 01.05.2015, p. 657-664.

Research output: Contribution to journalArticle

Coletta, D. K. ; Fernandez, M. ; Cersosimo, E. ; Gastaldelli, A. ; Musi, N. ; Defronzo, R. A. / The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. In: Diabetic Medicine. 2015 ; Vol. 32, No. 5. pp. 657-664.
@article{257ea33884d148c68e3bf88bcefc9805,
title = "The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo",
abstract = "Aims: The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. We hypothesized that muraglitazar would increase expression of 5′-monophosphate-activated protein kinase and genes involved in adiponectin signalling, free fatty acid oxidation and mitochondrial function in skeletal muscle. Methods: Sixteen participants with Type 2 diabetes received muraglitazar, 5 mg/day (n = 12) or placebo (n = 4). Before and after 16 weeks, participants had vastus lateralis muscle biopsy followed by 180 min euglycaemic hyperinsulinaemic clamp. Results: Muraglitazar increased plasma adiponectin (9.0 ± 1.1 to 17.8 ± 1.5 μg/ml, P < 0.05), while no significant change was observed with placebo. After 16 weeks with muraglitazar, fasting plasma glucose declined by 31{\%}, fasting plasma insulin decreased by 44{\%}, insulin-stimulated glucose disposal increased by 81{\%}, HbA1c decreased by 21{\%} and plasma triglyceride decreased by 39{\%} (all P < 0.05). Muraglitazar increased mRNA levels of 5′-monophosphate-activated protein kinase, adiponectin receptor 1, adiponectin receptor 2, peroxisome proliferator-activated receptor gamma coactivator-1 alpha and multiple genes involved in mitochondrial function and fat oxidation. In the placebo group, there were no significant changes in expression of these genes. Conclusions: Muraglitazar increases plasma adiponectin, stimulates muscle 5′-monophosphate-activated protein kinase expression and increases expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation. These changes represent important cellular mechanisms by which dual peroxisome proliferator-activated receptor agonists improve skeletal muscle insulin sensitivity.",
author = "Coletta, {D. K.} and M. Fernandez and E. Cersosimo and A. Gastaldelli and N. Musi and Defronzo, {R. A.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/dme.12664",
language = "English (US)",
volume = "32",
pages = "657--664",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo

AU - Coletta, D. K.

AU - Fernandez, M.

AU - Cersosimo, E.

AU - Gastaldelli, A.

AU - Musi, N.

AU - Defronzo, R. A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Aims: The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. We hypothesized that muraglitazar would increase expression of 5′-monophosphate-activated protein kinase and genes involved in adiponectin signalling, free fatty acid oxidation and mitochondrial function in skeletal muscle. Methods: Sixteen participants with Type 2 diabetes received muraglitazar, 5 mg/day (n = 12) or placebo (n = 4). Before and after 16 weeks, participants had vastus lateralis muscle biopsy followed by 180 min euglycaemic hyperinsulinaemic clamp. Results: Muraglitazar increased plasma adiponectin (9.0 ± 1.1 to 17.8 ± 1.5 μg/ml, P < 0.05), while no significant change was observed with placebo. After 16 weeks with muraglitazar, fasting plasma glucose declined by 31%, fasting plasma insulin decreased by 44%, insulin-stimulated glucose disposal increased by 81%, HbA1c decreased by 21% and plasma triglyceride decreased by 39% (all P < 0.05). Muraglitazar increased mRNA levels of 5′-monophosphate-activated protein kinase, adiponectin receptor 1, adiponectin receptor 2, peroxisome proliferator-activated receptor gamma coactivator-1 alpha and multiple genes involved in mitochondrial function and fat oxidation. In the placebo group, there were no significant changes in expression of these genes. Conclusions: Muraglitazar increases plasma adiponectin, stimulates muscle 5′-monophosphate-activated protein kinase expression and increases expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation. These changes represent important cellular mechanisms by which dual peroxisome proliferator-activated receptor agonists improve skeletal muscle insulin sensitivity.

AB - Aims: The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. We hypothesized that muraglitazar would increase expression of 5′-monophosphate-activated protein kinase and genes involved in adiponectin signalling, free fatty acid oxidation and mitochondrial function in skeletal muscle. Methods: Sixteen participants with Type 2 diabetes received muraglitazar, 5 mg/day (n = 12) or placebo (n = 4). Before and after 16 weeks, participants had vastus lateralis muscle biopsy followed by 180 min euglycaemic hyperinsulinaemic clamp. Results: Muraglitazar increased plasma adiponectin (9.0 ± 1.1 to 17.8 ± 1.5 μg/ml, P < 0.05), while no significant change was observed with placebo. After 16 weeks with muraglitazar, fasting plasma glucose declined by 31%, fasting plasma insulin decreased by 44%, insulin-stimulated glucose disposal increased by 81%, HbA1c decreased by 21% and plasma triglyceride decreased by 39% (all P < 0.05). Muraglitazar increased mRNA levels of 5′-monophosphate-activated protein kinase, adiponectin receptor 1, adiponectin receptor 2, peroxisome proliferator-activated receptor gamma coactivator-1 alpha and multiple genes involved in mitochondrial function and fat oxidation. In the placebo group, there were no significant changes in expression of these genes. Conclusions: Muraglitazar increases plasma adiponectin, stimulates muscle 5′-monophosphate-activated protein kinase expression and increases expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation. These changes represent important cellular mechanisms by which dual peroxisome proliferator-activated receptor agonists improve skeletal muscle insulin sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=84928047768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928047768&partnerID=8YFLogxK

U2 - 10.1111/dme.12664

DO - 10.1111/dme.12664

M3 - Article

C2 - 25484175

AN - SCOPUS:84928047768

VL - 32

SP - 657

EP - 664

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 5

ER -